STOCK TITAN
  1. Home
  2. Sec-filings
  3. APRE
  4. [Form 4] Aprea Therapeutics, Inc. Insider Trading Activity

Aprea Therapeutics (NASDAQ: APRE) CEO receives new equity awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aprea Therapeutics president and CEO Gilad Oren reported new equity awards. He received stock options for 80,700 shares of common stock at an exercise price of $0.765 per share, expiring on March 12, 2036. These options vest 25% on March 12, 2027, with the remainder vesting ratably over the following 36 months, subject to continued employment.

Oren was also granted 20,175 restricted stock units that vest in three equal annual installments beginning on March 12, 2027, also subject to continued employment. Following these grants, he directly holds 393,895 shares of common stock. Additional indirect holdings of 1,200 and 600 shares are reported for his daughter and son, with beneficial ownership disclaimed.

Positive

  • None.

Negative

  • None.
Insider Gilad Oren
Role President/CEO
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) 80,700 $0.00 --
Grant/Award Common Stock 20,175 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Options (Right to Buy) — 80,700 shares (Direct); Common Stock — 393,895 shares (Direct); Common Stock — 1,200 shares (Indirect, By Daughter)
Footnotes (1)
  1. These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gilad Oren
(Last) (First) (Middle)
3805 OLD EASTON ROAD
(Street)
DOYLESTOWN PA 18902
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aprea Therapeutics, Inc. [ APRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President/CEO
3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/12/2026 A 20,175(1) A $0.00 393,895 D
Common Stock 1,200 I(2) By Daughter
Common Stock 600 I(2) By Son
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $0.765 03/12/2026 A 80,700 (3) 03/12/2036 Common Stock 80,700 $0.00 80,700 D
Explanation of Responses:
1. These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
2. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
3. Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
/s/ John P. Hamill, as Attorney-in-Fact 03/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Aprea Therapeutics (APRE) disclose in Gilad Oren’s latest Form 4?

Aprea Therapeutics reported that CEO Gilad Oren received new equity awards, including stock options and restricted stock units. These are compensation-related grants, not open-market purchases, and they increase his reported direct and indirect exposure to Aprea common stock over time.

How many stock options were granted to Aprea Therapeutics CEO Gilad Oren?

Gilad Oren received stock options covering 80,700 shares of Aprea common stock at an exercise price of $0.765 per share. The options expire on March 12, 2036 and vest over four years, starting on March 12, 2027, subject to his continued employment.

What restricted stock units (RSUs) did Gilad Oren receive from Aprea Therapeutics (APRE)?

Gilad Oren was granted 20,175 restricted stock units that will settle in Aprea common stock. These RSUs vest in three equal annual installments beginning on March 12, 2027, assuming he remains employed through each vesting date or qualifies for any applicable acceleration conditions.

How many Aprea Therapeutics shares does Gilad Oren hold after these grants?

After the reported transactions, Gilad Oren directly holds 393,895 shares of Aprea common stock. The filing also lists 1,200 shares held by his daughter and 600 shares held by his son, for which he disclaims beneficial ownership under the stated Section 16 footnote.

Are Gilad Oren’s Aprea Therapeutics equity awards open-market stock purchases?

No, the reported transactions are compensation-related grants, not open-market purchases. The Form 4 uses code “A” for grant or award acquisitions, covering stock options and restricted stock units that vest over time rather than immediate market transactions for cash consideration.

What are the vesting conditions for Gilad Oren’s new Aprea Therapeutics equity awards?

The RSUs vest in three equal annual installments starting on March 12, 2027, while 25% of the options vest that same date and the rest over 36 months. Both awards require his continued employment and may accelerate only under specified conditions described in the footnotes.